1Shoelson, SE, Lee, J & Goldfine, AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793–1801.
2Lu, L, Zhang, Q, Pu, LJ, et al. (2007) Elevation of tumor necrosis factor-α, interleukin-1β and interleukin-6 levels in aortic intima of Chinese Guizhou minipigs with streptozotocin-induced diabetes. Chin Med J (Engl) 120, 479–484.
3Wen, Y, Gu, J, Li, SL, et al. (2006) Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology 147, 2518–2525.
4Hui, H, Dotta, F, Di Mario, U, et al. (2004) Role of caspases in the regulation of apoptotic pancreatic islet β-cells death. J Cell Physiol 200, 177–200.
5Jorns, A, Gunther, A, Hedrich, HJ, et al. (2005) Immune cell infiltration, cytokine expression, and β-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 54, 2041–2052.
6Montolio, M, Biarnes, M, Tellez, N, et al. (2007) Interleukin-1β and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J Endocrinol 192, 169–177.
7Hoge, M & Amar, S (2006) Role of interleukin-1 in bacterial atherogenesis. Drugs Today (Barc) 42, 683–688.
8Mahmoudi, M, Curzen, N & Gallagher, PJ (2007) Atherogenesis: the role of inflammation and infection. Histopathology 50, 535–546.
9Spranger, J, Kroke, A, Mohlig, M, et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812–817.
10Kim, ES, Im, JA, Kim, KC, et al. (2007) Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity (Silver Spring) 15, 3023–3030.
11Bruun, JM, Stallknecht, B, Helge, JW, et al. (2007) Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157, 465–471.
12Bonora, E (2002) Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 129, 5–11.
13Jellema, A, Plat, J & Mensink, RP (2004) Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 34, 766–773.
14Gill, JM, Al-Mamari, A, Ferrell, WR, et al. (2004) Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. J Am Coll Cardiol 44, 2375–2382.
15Kempf, K, Rose, B, Herder, C, et al. (2007) The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression. J Mol Med 85, 389–396.
16Goda, T, Suruga, K, Komori, A, et al. (2007) Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. Br J Nutr 98, 702–710.
17Puls, W, Krause, HP, Muller, L, et al. (1984) Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. Int J Obes 8 Suppl., 1, 181–190.
18Livak, KJ & Schmittgen, TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25, 402–408.
19Prins, JB (2002) Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab 16, 639–651.
20Flanagan, AM, Brown, JL, Santiago, CA, et al. (2007) High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem 19, 505–513.
21Nakamura, K, Yamagishi, S, Matsui, T, et al. (2005) Acarbose, an α-glucosidase inhibitor, improves insulin resistance in fructose-fed rats. Drugs Exp Clin Res 31, 155–159.
22Rachmani, R, Bar-Dayan, Y, Ronen, Z, et al. (2004) The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes Metab 6, 63–68.
23Koyama, M, Wada, R, Mizukami, H, et al. (2000) Inhibition of progressive reduction of islet β-cell mass in spontaneously diabetic Goto-Kakizaki rats by α-glucosidase inhibitor. Metabolism 49, 347–352.
24Chiasson, JL (2006) Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 12 Suppl., 1, 25–30.
25Chiasson, JL, Josse, RG, Gomis, R, et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077.
26Mita, T, Otsuka, A, Azuma, K, et al. (2007) Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 358, 679–685.
27Giugliano, D, Ceriello, A & Esposito, K (2008) Glucose metabolism and hyperglycemia. Am J Clin Nutr 87, 217S–222S.
28Chiasson, JL, Josse, RG, Gomis, R, et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486–494.
29Zeymer, U, Schwarzmaier-D'assie, A, Petzinna, D, et al. (2004) Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 11, 412–415.